Oxoglaucine mediates Ca2+ influx and activates autophagy to alleviate osteoarthritis through the TRPV5/calmodulin/CAMK-II pathway.

Published in: British journal of pharmacology (2021)

Oxoglaucine protects against cartilage damage by blocking the TRPV5/CAMK-II/calmodulin pathway to inhibit Ca2+ influx and activate autophagy. Our results indicate that oxoglaucine has the potential to become a candidate drug for treatment of OA.

Keyphrases

protein kinase
oxidative stress
cell death
endoplasmic reticulum stress
signaling pathway
knee osteoarthritis
neuropathic pain
rheumatoid arthritis
spinal cord injury
risk assessment
spinal cord
drug induced
adverse drug
electronic health record